Brazil’s National Health Surveillance Agency (Anvisa) received a request for phase 3 clinical trials for the Sputnik V vaccine, developed in Russia, in Brazil.
The request was made by the União Química laboratory and must be answered within 72 hours. In phase 3, more extensive tests are carried out with humans. The step is mandatory to authorize the use of an immunizer.
Information on the research schedule and how many people in Brazil should participate in the tests with Sputnik V are included in the request, but have not yet been released.
Four vaccines have already received authorization to carry out phase 3 tests in Brazil: Aztrazeneca/Oxford, developed in the United Kingdom; Coronavac, by Sinovac, developed in China; and that of Pfizer/BioNTech, developed in Germany and the United States.
On Tuesday, Argentina began to vaccinate its citizens against the COVID-19 using Sputnik V. Last week, 300,000 doses of the Russian vaccine were delivered in the country.
Latin America’s third-largest economy registered nearly 1.6 million cases of the disease and 42,868 deaths since the beginning of the COVID-19 pandemic, in March.
In August, the state government of Paraná signed an agreement with Russia for technology transfer and production of the Sputnik V vaccine by the Paraná Institute of Technology (Tecpar). In September, the Paraná laboratory informed that it planned to start the tests in October. Now, the expectation is that this will only occur in February or March.